J Cancer 2019; 10(21):5212-5222. doi:10.7150/jca.31697

Research Paper

AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma

Zhenfeng Zhao1,2,#, Shuguang Zhou3,#, Wenyu Li1,#, Fei Zhong4,#, Heping Zhang5, Lei Sheng1, Yue Li1, Meng Xu1, Jifei Xu1, Lei Zhan6, Bao Li7, Fan Wang1, Dan Xie8, Zhuting Tong1✉

1. Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2. Department of Radiation Oncology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
3. Department of Gynecology, Maternity and Child Healthcare Hospital of Anhui Medical University, Hefei, China
4. Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China
5. Department of Pathology, Maternity and Child Healthcare Hospital of Anhui Medical University, Hefei, China
6. Pathology Department of Anhui Medical University, Hefei, China
7. The Comprehensive Lab, College of Basic medicine, Anhui Medical University, Hefei, China
8. State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China
# These authors have contributed equally to this work.

Abstract

Amplified in breast cancer 1 (AIB1) gene, has been reported to be associated with biological malignancy in several cancers. However, the molecular status of the AIB1 gene in cervical cancer and the clinicopathological/prognostic significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity have not been determined. In our present study, we found that the high expression of AIB1 was frequent detected in specimens of cervical cancer patients, and this was significantly correlated with CRT response (P = 0.014), clinical stage (P = 0.003), T status (P = 0.027), N status (P = 0.021), M status (P = 0.015) and progression-free survival (P < 0.001). Moreover, the clonogenic survival fraction and cell apoptosis experiments showed that knockdown of AIB1 substantially increased cervical cancer cells sensitivity to ionizing radiation (IR) or cisplatin/5-fluorouracil. Collectively, our results demonstrated that the high expression of AIB1 in cervical cancer cells contributes to the resistance to CRT, which provides the evidence that AIB1 may be a promising predictor of aggressive cervical cancer patients with poor response to CRT.

Keywords: Cervical cancer, AIB1, immunohistochemistry, chemoradiotherapy, Linear-Quadratic Model

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhao Z, Zhou S, Li W, Zhong F, Zhang H, Sheng L, Li Y, Xu M, Xu J, Zhan L, Li B, Wang F, Xie D, Tong Z. AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma. J Cancer 2019; 10(21):5212-5222. doi:10.7150/jca.31697. Available from http://www.jcancer.org/v10p5212.htm